NextCure, Inc. (NXTC)
NXTC Stock Price Chart
Explore NextCure, Inc. interactive price chart. Choose custom timeframes to analyze NXTC price movements and trends.
NXTC Company Profile
Discover essential business fundamentals and corporate details for NextCure, Inc. (NXTC) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
9 May 2019
Employees
43.00
Website
https://www.nextcure.comCEO
Michael S. Richman MSBA
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NXTC Financial Timeline
Browse a chronological timeline of NextCure, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 29 Apr 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$4.06.
Earnings released on 7 Aug 2025
EPS came in at -$11.29 falling short of the estimated -$4.62 by -144.37%.
Stock split effective on 14 Jul 2025
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 1 May 2025
EPS came in at -$4.68 surpassing the estimated -$4.80 by +2.50%.
Earnings released on 6 Mar 2025
EPS came in at -$0.41 falling short of the estimated -$0.34 by -20.59%.
Earnings released on 7 Nov 2024
EPS came in at -$0.41 falling short of the estimated -$0.35 by -17.14%.
Earnings released on 1 Aug 2024
EPS came in at -$0.55 falling short of the estimated -$0.36 by -52.78%.
Earnings released on 2 May 2024
EPS came in at -$0.61 falling short of the estimated -$0.45 by -35.56%.
Earnings released on 21 Mar 2024
EPS came in at -$0.52 surpassing the estimated -$0.54 by +3.70%, while revenue for the quarter reached $6.28M .
Earnings released on 2 Nov 2023
EPS came in at -$0.51 surpassing the estimated -$0.64 by +20.31%.
Earnings released on 3 Aug 2023
EPS came in at -$0.64 falling short of the estimated -$0.60 by -6.67%.
Earnings released on 4 May 2023
EPS came in at -$0.58 surpassing the estimated -$0.64 by +9.38%.
Earnings released on 2 Mar 2023
EPS came in at -$0.62 surpassing the estimated -$0.65 by +4.62%.
Earnings released on 3 Nov 2022
EPS came in at -$0.68 falling short of the estimated -$0.60 by -13.33%.
Earnings released on 4 Aug 2022
EPS came in at -$0.65 surpassing the estimated -$0.73 by +10.96%.
Earnings released on 5 May 2022
EPS came in at -$0.74 falling short of the estimated -$0.68 by -8.82%.
Earnings released on 3 Mar 2022
EPS came in at -$0.61 surpassing the estimated -$0.67 by +8.96%.
Earnings released on 4 Nov 2021
EPS came in at -$0.65 surpassing the estimated -$0.67 by +2.99%.
Earnings released on 5 Aug 2021
EPS came in at -$0.65 falling short of the estimated -$0.60 by -8.33%.
Earnings released on 6 May 2021
EPS came in at -$0.60 falling short of the estimated -$0.57 by -5.26%.
Earnings released on 4 Mar 2021
EPS came in at -$0.56 surpassing the estimated -$0.58 by +3.45%, while revenue for the quarter reached $0.00 .
Earnings released on 5 Nov 2020
EPS came in at -$0.59 falling short of the estimated -$0.56 by -5.36%.
NXTC Stock Performance
Access detailed NXTC performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.